Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density

Autor: Carlos Mautalen, Y.-C. Yang, K Poole, Christopher Recknor, Andreas Grauer, M. A. Bolognese, Graham M. Treece, David A. Hanley, RA Pearson, Tristan Whitmarsh, Andrew H. Gee, Jacques P. Brown, Cesar Libanati, Stefan Goemaere, Maria Rojeski

Publikováno v: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 37(2)

Funder: NIHR Cambridge BRC; Id: http://dx.doi.org/10.13039/501100018956
Romosozumab monoclonal antibody treatment works by binding sclerostin and causing rapid stimulation of bone formation while decreasing bone resorption. The location and loca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aba7093d8d513c362a6e191dd1dbde9
https://pubmed.ncbi.nlm.nih.gov/34738660

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

Autor: C. Wang, M. A. Bolognese, Jean-Yves Reginster, Steve Cummings, Henry G. Bone, Rachel B. Wagman, A. Singer, Edward Czerwiński, Nicola Pannacciulli, Paul D. Miller, Jorge Malouf, Jacques P. Brown, Bettina S. Nedergaard

Publikováno v: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
The Journal of Clinical Endocrinology and Metabolism

Context: Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis. Objective: The objective of the study was to compare the effect of transitioning from oral bisphosphonates to denosumab or ZOL on bone mineral dens

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9945a415e577cb16e363b1a0f7cc0169
https://doi.org/10.1210/jc.2016-1801

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

Autor: Robert R. Recker, Claus Christiansen, Daiva Masanauskaite, Penelope Ward, Dieter Felsenberg, Jean-Yves Reginster, Silvano Adami, Pierre D. Delmas, Roberto Civitelli, J. A. Stakkestad, C. Hughes, Marc K. Drezner, Philip N. Sambrook, Cezary Strugala, M. A. Bolognese, David M. Reid

Publikováno v: Arthritis & Rheumatism. 54:1838-1846

Objective Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously administered bisphosphonate could be beneficial for such patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3514da722ef2112af9af2e99c5f2059
https://doi.org/10.1002/art.21918

Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate

Autor: C. Recknor, J. W. Hall, Sydney Lou Bonnick, P. Dakin, Irene Ferreira, J. van den Bergh, Henry G. Bone, P.R. Ho, Rachel B. Wagman, Jacques P. Brown, C. Roux, M. A. Bolognese

Publikováno v: Osteoporosis International, 25(7), 1953-1961. Springer-Verlag London Ltd.

Managing osteoporotic patients suboptimally adherent to bisphosphonates (BPs) is difficult. Such patients who remained at higher risk for fracture (a parts per thousand yen1 risk factor) were transitioned to denosumab or a monthly oral BP. Denosumab-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e494d0a0fe565c2a47edd99d91cc6dc
https://cris.maastrichtuniversity.nl/en/publications/dc75943a-82aa-41df-ae81-5926016fc8f0

OP0100 Superior Gains in Bone Mineral Density and Estimated Strength at The Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of The Phase 3 Open-Label Structure Study

Autor: Cesar Libanati, Lars Hyldstrup, M. A. Bolognese, Stefan Goemaere, F. Massari, Daria B. Crittenden, Judy Maddox, E. Jodar-Gimeno, Bente L. Langdahl, Klaus Engelke, Jorge Malouf, Nadia Daizadeh, Joel S. Finkelstein, M. Ulla, J F Molina, P. Lakatos, E Dokoupilova, Harry K. Genant, Andreas Grauer, David L. Kendler, Jamie N. Brown, Tony M. Keaveny

Publikováno v: Annals of the Rheumatic Diseases. 75:92.2-93

Background In a phase 2 study, treatment with romosozumab significantly increased bone mass in women with low bone mineral density (BMD). Objectives To report the results of STRUCTURE, a phase 3 study evaluating the effect of romosozumab or teriparat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::48968d83d7e4174d559cafa7f33d87d5
https://doi.org/10.1136/annrheumdis-2016-eular.1163